Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 10/20 | 0.68 |
| ▸ | HTR2B | P41595 | 7/20 | 0.68 |
| ▸ | HTR2A | P28223 | 4/20 | 0.62 |
| ▸ | MET | P08581 | 1/20 | 0.47 |
| ▸ | DRD2 | P14416 | 1/20 | 0.45 |
| ▸ | DRD3 | P35462 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | RELA | Q04206 | 1/20 | 0.41 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6410260 | 0.87 | HTR2C (0.57) | HTR2CHTR2BHTR2AMETKMT2A | |
| SCHEMBL6415389 | 0.85 | HTR2C (0.52) | HTR2CHTR2BHTR2AMETPOLB | |
| SCHEMBL6410238 | 0.81 | HTR2C (1.00) | HTR2CHTR2BHTR2A | |
| SCHEMBL6414662 | 0.78 | HTR2C (0.72) | HTR2CHTR2BHTR2APOLBKMT2A | |
| SCHEMBL6415386 | 0.78 | HTR2C (0.61) | HTR2CHTR2BHTR2APOLBKMT2A | |
| SCHEMBL6415416 | 0.77 | HTR2C (1.00) | HTR2CHTR2BHTR2A | |
| SCHEMBL6414633 | 0.77 | HTR2C (0.62) | HTR2CHTR2BHTR2AKMT2AMEN1 | |
| SCHEMBL6408486 | 0.76 | HTR2C (1.00) | HTR2CHTR2BHTR2A | |
| SCHEMBL6414146 | 0.76 | HTR2C (0.74) | HTR2CHTR2BHTR2A | |
| SCHEMBL6417254 | 0.74 | HTR2C (0.71) | HTR2CHTR2BHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6960688-B2 | Use of compounds for the elevation of pyruvate dehydrogenase activity | ASTRAZENECA AB (SE) | 2005-11-01 | — | — | US | disclosed |
| US-20050154028-A1 | Cyclic urea derivatives with 5-ht2c receptor activity | GLAXO GROUP LIMITED (GB) | 2005-07-14 | — | — | US | disclosed |
| EP-1465630-A1 | CYCLIC UREA DERIVATIVES WITH 5-HT2C RECEPTOR ACTIVITY | GLAXO GROUP LIMITED (GB) | 2004-10-13 | — | — | EP | disclosed |
| EP-1082110-B1 | USE OF COMPOUNDS FOR THE ELEVATION OF PYRUVATE DEHYDROGENASE ACTIVITY | ASTRAZENECA AB (SE) | 2004-03-24 | — | — | EP | disclosed |
| US-20040009979-A1 | Use of compounds for the elevation of pyruvate dehydrogenase activity | ZENECA LIMITED | 2004-01-15 | — | — | US | disclosed |
| WO-2003057220-A1 | CYCLIC UREA DERIVATIVES WITH 5-HT2C RECEPTOR ACTIVITY | GLAXO GROUP LIMITED (GB) | 2003-07-17 | — | — | WO | disclosed |
| US-6498275-B1 | Use of compounds for the elevation of pyruvate dehydrogenase activity | ASTRAZENECA AB (SE) | 2002-12-24 | — | — | US | disclosed |
| CN-1303281-A | Application of compound in enhancing activity of pyruvate dehydrogenase | ASTRA ZENECA LTD (SE) | 2001-07-11 | — | — | CN | disclosed |
| EP-1082110-A1 | USE OF COMPOUNDS FOR THE ELEVATION OF PYRUVATE DEHYDROGENASE ACTIVITY | AstraZeneca AB (SE) | 2001-03-14 | — | — | EP | disclosed |
| WO-1999062506-A1 | USE OF COMPOUNDS FOR THE ELEVATION OF PYRUVATE DEHYDROGENASE ACTIVITY | ASTRAZENECA AB (SE) | 1999-12-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050154028-A1 | Cyclic urea derivatives with 5-ht2c receptor activity | HTR2C, HTR3C, HTR5A | HTR2C 1/4885HTR2B 28/4885HTR2A 30/4885 |
| US-20040009979-A1 | Use of compounds for the elevation of pyruvate dehydrogenase activity | PDHA1, PDK1, PDHB | HTR2C 3932/4885HTR2B 4017/4885HTR2A 4569/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.